A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

ClinicalTrials.gov ID: NCT01882803

Public ClinicalTrials.gov record NCT01882803. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This was a Phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in participants with indolent non-Hodgkin lymphoma (iNHL) (follicular lymphoma \[FL\], marginal zone lymphoma, or small lymphocytic lymphoma) that was refractory to rituximab and to either chemotherapy or radioimmunotherapy (RIT).

Study identification

NCT ID: NCT01882803
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: SecuraBio; Industry
Enrollment: 129 participants

Conditions and interventions

Conditions

Indolent Non-Hodgkin Lymphoma

Interventions

Duvelisib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 16, 2013
Primary completion: Nov 17, 2020
Completion: Nov 17, 2020
Last update posted: Sep 6, 2023

2013 – 2020

United States locations

U.S. sites: 24
U.S. states: 17
U.S. cities: 23

Facility	City	State	ZIP	Site status
Not listed	Los Angeles	California	90095-6984	—
Not listed	Whittier	California	90603	—
Not listed	Denver	Colorado	80218	—
Not listed	Fort Myers	Florida	39916	—
Not listed	St. Petersburg	Florida	33705	—
Not listed	Tallahassee	Florida	32308	—
Not listed	Atlanta	Georgia	30322	—
Not listed	Chicago	Illinois	60637	—
Not listed	Louisville	Kentucky	40207	—
Not listed	Baltimore	Maryland	21204	—
Not listed	Baltimore	Maryland	21229	—
Not listed	Boston	Massachusetts	02215	—
Not listed	St Louis	Missouri	63110	—
Not listed	Howell Township	New Jersey	07731	—
Not listed	Morristown	New Jersey	07962	—
Not listed	New York	New York	10021	—
Not listed	Rockville Centre	New York	11510	—
Not listed	Canton	Ohio	44718	—
Not listed	Lawton	Oklahoma	73505	—
Not listed	Oklahoma City	Oklahoma	73104	—
Not listed	Philadelphia	Pennsylvania	01911	—
Not listed	Nashville	Tennessee	37203	—
Not listed	Dallas	Texas	75246	—
Not listed	Lynchburg	Virginia	24501	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01882803, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 6, 2023 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01882803 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →